Cell culture-derived influenza vaccine (Influvac TC) - AbbVie

Drug Profile

Cell culture-derived influenza vaccine (Influvac TC) - AbbVie

Alternative Names: Influvac TC; Influvac TC (cell-based seasonal vaccine); Influvac® TC EU; Influvac® TC US

Latest Information Update: 25 Aug 2015

Price : $50

At a glance

  • Originator Solvay Pharmaceuticals
  • Developer Abbott Laboratories; Solvay Pharmaceuticals
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Influenza virus infections

Most Recent Events

  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
  • 16 Feb 2010 Solvay Pharmaceuticals has been acquired and merged into Abbott Laboratories
  • 12 Feb 2010 Phase-I development in the US, and phase-III development in the EU, is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top